WO2005123131A3 - High pressure spray-dry of bioactive materials - Google Patents

High pressure spray-dry of bioactive materials Download PDF

Info

Publication number
WO2005123131A3
WO2005123131A3 PCT/US2005/020792 US2005020792W WO2005123131A3 WO 2005123131 A3 WO2005123131 A3 WO 2005123131A3 US 2005020792 W US2005020792 W US 2005020792W WO 2005123131 A3 WO2005123131 A3 WO 2005123131A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioactive materials
high pressure
dry
pressure spray
powder particles
Prior art date
Application number
PCT/US2005/020792
Other languages
French (fr)
Other versions
WO2005123131A2 (en
Inventor
Vu Truong-Le
Tom Scherer
Original Assignee
Medimmune Vaccines Inc
Vu Truong-Le
Tom Scherer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines Inc, Vu Truong-Le, Tom Scherer filed Critical Medimmune Vaccines Inc
Priority to JP2007527797A priority Critical patent/JP2008505192A/en
Priority to AU2005254062A priority patent/AU2005254062B2/en
Priority to EP05770439A priority patent/EP1755677A4/en
Priority to CA002564791A priority patent/CA2564791A1/en
Publication of WO2005123131A2 publication Critical patent/WO2005123131A2/en
Publication of WO2005123131A3 publication Critical patent/WO2005123131A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

This invention provides compositions and methods providing, e.g., stable powder particles containing bioactive materials. The methods include, e.g., high pressure spraying of the bioactive materials in solution or suspension, with viscosity enhancing agents, organic solvents, and/or surfactants. Formulations are provided for spraying therapeutic bioactive materials into powder particles containing amino acids and sugars. Compositions of the invention provide, e.g., high initial purity, high stability in storage, and reconstitution at high concentrations.
PCT/US2005/020792 2002-04-11 2005-06-13 High pressure spray-dry of bioactive materials WO2005123131A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007527797A JP2008505192A (en) 2004-06-14 2005-06-13 High pressure spray drying of bioactive materials
AU2005254062A AU2005254062B2 (en) 2002-04-11 2005-06-13 High pressure spray-dry of bioactive materials
EP05770439A EP1755677A4 (en) 2004-06-14 2005-06-13 High pressure spray-dry of bioactive materials
CA002564791A CA2564791A1 (en) 2004-06-14 2005-06-13 High pressure spray-dry of bioactive materials

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57985004P 2004-06-14 2004-06-14
US60/579,850 2004-06-14

Publications (2)

Publication Number Publication Date
WO2005123131A2 WO2005123131A2 (en) 2005-12-29
WO2005123131A3 true WO2005123131A3 (en) 2008-01-03

Family

ID=35510270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/020792 WO2005123131A2 (en) 2002-04-11 2005-06-13 High pressure spray-dry of bioactive materials

Country Status (5)

Country Link
EP (1) EP1755677A4 (en)
JP (1) JP2008505192A (en)
AU (1) AU2005254062B2 (en)
CA (1) CA2564791A1 (en)
WO (1) WO2005123131A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115357B2 (en) 2004-05-12 2015-08-25 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
US9339465B2 (en) 2004-05-12 2016-05-17 Baxter International, Inc. Nucleic acid microspheres, production and delivery thereof
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105555376B (en) * 2013-03-28 2017-05-17 英斯迪罗有限公司 Apparatus and method for producing dispersions and solids

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
US8268354B2 (en) * 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
WO2010038076A1 (en) 2008-10-02 2010-04-08 Pharmathene Uk Limited Anthrax vaccine formulation and uses thereof
EP2432502B1 (en) 2009-05-20 2018-01-03 Aeras Stable, spray dried, immunogenic, viral compositions
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
CN102939098B (en) 2010-03-01 2016-08-03 拜耳医药保健有限公司 Monoclonal antibody for the optimization of tissue factor approach restrainer (TFPI)
BR112012030139A2 (en) 2010-05-28 2017-06-13 Novo Nordisk As stable multiple dose antibody compositions comprising an antibody and a preservative
DK2691415T3 (en) 2011-03-28 2018-10-29 Ablynx Nv PROCEDURE FOR PREPARING SOLID FORMULATIONS CONTAINING VARIABLE SINGLE DOMAINS OF IMMUNOGLOBULIN
ITMI20112042A1 (en) * 2011-11-10 2013-05-11 Eratech S R L POWDER TO RECONSTITUTE BEFORE INCLUDING MELATONIN AND INJECTABLE PREPARATION OBTAINABLE FROM SUCH POWDER.
WO2018078186A1 (en) * 2016-10-31 2018-05-03 Vectura Limited Inhalable powder composition comprising il-13 antibody
EP3459529A1 (en) * 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040042971A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913177A1 (en) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CN101287449B (en) * 2002-04-11 2010-11-03 米迪缪尼有限公司 Preservation of bioactive materials by spray drying
CA2508592A1 (en) * 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040042971A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1755677A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115357B2 (en) 2004-05-12 2015-08-25 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
US9339465B2 (en) 2004-05-12 2016-05-17 Baxter International, Inc. Nucleic acid microspheres, production and delivery thereof
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105555376B (en) * 2013-03-28 2017-05-17 英斯迪罗有限公司 Apparatus and method for producing dispersions and solids

Also Published As

Publication number Publication date
WO2005123131A2 (en) 2005-12-29
EP1755677A2 (en) 2007-02-28
AU2005254062A1 (en) 2005-12-29
AU2005254062B2 (en) 2011-02-17
CA2564791A1 (en) 2005-12-29
JP2008505192A (en) 2008-02-21
EP1755677A4 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2005123131A3 (en) High pressure spray-dry of bioactive materials
WO2004058156A3 (en) High pressure spray-dry of bioactive materials
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2003087335A3 (en) Preservation of bioactive materials by spray drying
WO2006051103A3 (en) Stable formulations of peptides
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
EP2269631A3 (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
WO2007043048A3 (en) Self-assembled fmoc-ff hydrogels
WO2003087339A3 (en) Spray freeze dry of compositions for pulmonary administration
WO2006026760A3 (en) 1-amino imidazo-containing compounds and methods
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
WO2004110352A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
NO20073059L (en) 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
WO2007016388A3 (en) Liquid formulations for controlled delivery of benzisoxazole derivatives
WO2010019266A3 (en) Linaclotide-containing formulations for oral administration
WO2005009393A3 (en) Stable radiopharmaceutical compositions and methods for preparation
ATE509634T1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT
IL185479A0 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
EP2279732A3 (en) Compounds and compositions for delivering active agents
AU2003218759A1 (en) Stabilization of resorcinol derivatives in cosmetic compositions
HK1058902A1 (en) Compositions for protein delivery via the pulmonary route
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
TW200731971A (en) Solid preparation
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2564791

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005254062

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005770439

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005254062

Country of ref document: AU

Date of ref document: 20050613

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005254062

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007527797

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005770439

Country of ref document: EP